{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T16:22:53Z","timestamp":1768666973617,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Burkitt leukemia\/lymphoma is a major subtype of aggressive B-cell lymphoma. Biological targeted therapies on this disease need to be further investigated and may help to improve the clinical outcome of the patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This study examined the anti-tumor activity of the histone deacetylases (HDAC) inhibitor valproic acid (VPA) combined with the mammalian target of rapamycin (MTOR) inhibitor temsirolimus in Burkitt leukemia\/lymphoma cell lines, as well as in primary tumor cells and a murine xenograft model.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Co-treatment of VPA and temsirolimus synergistically inhibited the tumor cell growth and triggered the autophagic cell death, with a significant inhibition of MTOR signaling and MYC oncoprotein. Functioned as a class I HDAC inhibitor, VPA potentiated the effect of temsirolimus on autophagy through inhibiting HDAC1. Molecular silencing of HDAC1 using small interfering RNA (siRNA) attenuated VPA-mediated regulation of CDKN1A, CDKN1B and LC3-I\/II, regression of tumor cell growth and induction of autophagy. Meanwhile, VPA counteracted temsirolimus-induced AKT activation via HDAC3 inhibition. HDAC3 siRNA abrogated the ability of VPA to modulate AKT phosphorylation, to suppress tumor cell growth and to induce autophagy. Strong antitumor effect was also observed on primary tumor cells while sparing normal hematopoiesis ex vivo. In a murine xenograft model established with subcutaneous injection of Namalwa cells, dual treatment efficiently blocked tumor growth, inhibited MYC and induced in situ autophagy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>These findings confirmed the synergistic effect of the HDAC and MTOR inhibitors on Burkitt leukemia\/lymphoma, and provided an insight into clinical application of targeting autophagy in treating MYC-associated lymphoid malignancies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1756-8722-6-53","type":"journal-article","created":{"date-parts":[[2013,7,18]],"date-time":"2013-07-18T10:14:46Z","timestamp":1374142486000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia\/lymphoma"],"prefix":"10.1186","volume":"6","author":[{"given":"Li Hua","family":"Dong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi Xiang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai Juan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,7,18]]},"reference":[{"issue":"2","key":"320_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ccr.2012.06.012","volume":"22","author":"S Sander","year":"2012","unstructured":"Sander S, Calado DP, Srinivasan L, Kochert K, Zhang B, Rosolowski M, Rodig SJ, Holzmann K, Stilgenbauer S, Siebert R: Synergy between PI3K Signaling and MYC in Burkitt Lymphomagenesis. Cancer Cell. 2012, 22 (2): 167-179. 10.1016\/j.ccr.2012.06.012.","journal-title":"Cancer Cell"},{"issue":"10","key":"320_CR2","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1182\/blood-2004-02-0405","volume":"104","author":"KA Blum","year":"2004","unstructured":"Blum KA, Lozanski G, Byrd JC: Adult Burkitt leukemia and lymphoma. Blood. 2004, 104 (10): 3009-3020. 10.1182\/blood-2004-02-0405.","journal-title":"Blood"},{"issue":"3","key":"320_CR3","doi-asserted-by":"publisher","first-page":"322","DOI":"10.4161\/auto.6.3.11625","volume":"6","author":"KN Dalby","year":"2010","unstructured":"Dalby KN, Tekedereli I, Lopez-Berestein G, Ozpolat B: Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy. 2010, 6 (3): 322-329. 10.4161\/auto.6.3.11625.","journal-title":"Autophagy"},{"issue":"7182","key":"320_CR4","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nature06639","volume":"451","author":"N Mizushima","year":"2008","unstructured":"Mizushima N, Levine B, Cuervo AM, Klionsky DJ: Autophagy fights disease through cellular self-digestion. Nature. 2008, 451 (7182): 1069-1075. 10.1038\/nature06639.","journal-title":"Nature"},{"issue":"12","key":"320_CR5","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1172\/JCI20039","volume":"112","author":"X Qu","year":"2003","unstructured":"Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, Rosen J, Eskelinen EL, Mizushima N, Ohsumi Y: Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest. 2003, 112 (12): 1809-1820.","journal-title":"J Clin Invest"},{"issue":"10","key":"320_CR6","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/j.humpath.2010.12.014","volume":"42","author":"JJ Huang","year":"2011","unstructured":"Huang JJ, Zhu YJ, Lin TY, Jiang WQ, Huang HQ, Li ZM: Beclin 1 expression predicts favorable clinical outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP. Hum Pathol. 2011, 42 (10): 1459-1466. 10.1016\/j.humpath.2010.12.014.","journal-title":"Hum Pathol"},{"issue":"6","key":"320_CR7","doi-asserted-by":"publisher","first-page":"777","DOI":"10.4161\/auto.6.6.12784","volume":"6","author":"JJ Huang","year":"2010","unstructured":"Huang JJ, Li HR, Huang Y, Jiang WQ, Xu RH, Huang HQ, Lv Y, Xia ZJ, Zhu XF, Lin TY: Beclin 1 expression: a predictor of prognosis in patients with extranodal natural killer T-cell lymphoma, nasal type. Autophagy. 2010, 6 (6): 777-783. 10.4161\/auto.6.6.12784.","journal-title":"Autophagy"},{"key":"320_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1756-8722-3-45","volume":"3","author":"PB Johnston","year":"2010","unstructured":"Johnston PB, Yuan R, Cavalli F, Witzig TE: Targeted therapy in lymphoma. J Hematol Oncol. 2010, 3: 45-10.1186\/1756-8722-3-45.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"320_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/nrm3025","volume":"12","author":"R Zoncu","year":"2011","unstructured":"Zoncu R, Efeyan A, Sabatini DM: mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011, 12 (1): 21-35. 10.1038\/nrm3025.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"320_CR10","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/asheducation-2010.1.265","volume":"2010","author":"TE Witzig","year":"2010","unstructured":"Witzig TE, Gupta M: Signal transduction inhibitor therapy for lymphoma. Hematology Am Soc Hematol Educ Program. 2010, 2010: 265-270. 10.1182\/asheducation-2010.1.265.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"320_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1756-8722-2-45","volume":"2","author":"R Yuan","year":"2009","unstructured":"Yuan R, Kay A, Berg WJ, Lebwohl D: Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol. 2009, 2: 45-10.1186\/1756-8722-2-45.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"320_CR12","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/35106079","volume":"1","author":"P Marks","year":"2001","unstructured":"Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK: Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001, 1 (3): 194-202. 10.1038\/35106079.","journal-title":"Nat Rev Cancer"},{"key":"320_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1756-8722-2-22","volume":"2","author":"S Cang","year":"2009","unstructured":"Cang S, Ma Y, Liu D: New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. J Hematol Oncol. 2009, 2: 22-10.1186\/1756-8722-2-22.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"320_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.exphem.2004.09.008","volume":"33","author":"S Sakajiri","year":"2005","unstructured":"Sakajiri S, Kumagai T, Kawamata N, Saitoh T, Said JW, Koeffler HP: Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol. 2005, 33 (1): 53-61. 10.1016\/j.exphem.2004.09.008.","journal-title":"Exp Hematol"},{"issue":"6","key":"320_CR15","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1080\/10428190701344907","volume":"48","author":"J Zain","year":"2007","unstructured":"Zain J, Rotter A, Weiss L, Forman S, Kirschbaum MH: Valproic acid monotherapy leads to CR in a patient with refractory diffuse large B cell lymphoma. Leuk Lymphoma. 2007, 48 (6): 1216-1218. 10.1080\/10428190701344907.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"320_CR16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1083\/jcb.200507002","volume":"171","author":"G Bjorkoy","year":"2005","unstructured":"Bjorkoy G, Lamark T, Brech A, Outzen H, Perander M, Overvatn A, Stenmark H, Johansen T: p62\/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol. 2005, 171 (4): 603-614. 10.1083\/jcb.200507002.","journal-title":"J Cell Biol"},{"issue":"5","key":"320_CR17","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell. 2011, 144 (5): 646-674. 10.1016\/j.cell.2011.02.013.","journal-title":"Cell"},{"issue":"5","key":"320_CR18","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1182\/blood-2010-06-255067","volume":"117","author":"CB Reeder","year":"2011","unstructured":"Reeder CB, Ansell SM: Novel therapeutic agents for B-cell lymphoma: developing rational combinations. Blood. 2011, 117 (5): 1453-1462. 10.1182\/blood-2010-06-255067.","journal-title":"Blood"},{"issue":"3","key":"320_CR19","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1210\/jc.2004-1355","volume":"90","author":"MG Catalano","year":"2005","unstructured":"Catalano MG, Fortunati N, Pugliese M, Costantino L, Poli R, Bosco O, Boccuzzi G: Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab. 2005, 90 (3): 1383-1389.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"320_CR20","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1200\/JCO.2004.08.116","volume":"22","author":"E Raymond","year":"2004","unstructured":"Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, Leister C, Korth-Bradley J, Hanauske A, Armand JP: Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol. 2004, 22 (12): 2336-2347. 10.1200\/JCO.2004.08.116.","journal-title":"J Clin Oncol"},{"issue":"4","key":"320_CR21","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/CAD.0b013e32835dc7c5","volume":"24","author":"DW Coulter","year":"2013","unstructured":"Coulter DW, Walko C, Patel J, Moats-Staats BM, McFadden A, Smith SV, Khan WA, Bridges AS, Deal AM, Oesterheld J, Davis IJ, Blatt J: Valproic acid reduces the tolerability of temsirolimus in children and adolescents with solid tumors. Anticancer Drugs. 2013, 24 (4): 415-421. 10.1097\/CAD.0b013e32835dc7c5.","journal-title":"Anticancer Drugs"},{"issue":"7","key":"320_CR22","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1002\/ijc.25477","volume":"128","author":"SM Cloonan","year":"2011","unstructured":"Cloonan SM, Williams DC: The antidepressants maprotiline and fluoxetine induce Type II autophagic cell death in drug-resistant Burkitt's lymphoma. Int J Cancer. 2011, 128 (7): 1712-1723. 10.1002\/ijc.25477.","journal-title":"Int J Cancer"},{"issue":"1","key":"320_CR23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1365-2141.2008.07555.x","volume":"145","author":"J Turzanski","year":"2009","unstructured":"Turzanski J, Daniels I, Haynes AP: Involvement of macroautophagy in the caspase-independent killing of Burkitt lymphoma cell lines by rituximab. Br J Haematol. 2009, 145 (1): 137-140. 10.1111\/j.1365-2141.2008.07555.x.","journal-title":"Br J Haematol"},{"issue":"4","key":"320_CR24","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.exphem.2007.12.008","volume":"36","author":"VY Yazbeck","year":"2008","unstructured":"Yazbeck VY, Buglio D, Georgakis GV, Li Y, Iwado E, Romaguera JE, Kondo S, Younes A: Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Exp Hematol. 2008, 36 (4): 443-450. 10.1016\/j.exphem.2007.12.008.","journal-title":"Exp Hematol"},{"issue":"4","key":"320_CR25","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/neuonc\/nop005","volume":"12","author":"J Fu","year":"2010","unstructured":"Fu J, Shao CJ, Chen FR, Ng HK, Chen ZP: Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines. Neuro Oncol. 2010, 12 (4): 328-340. 10.1093\/neuonc\/nop005.","journal-title":"Neuro Oncol"},{"issue":"1","key":"320_CR26","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.canlet.2011.11.036","volume":"318","author":"R Francisco","year":"2012","unstructured":"Francisco R, Perez-Perarnau A, Cortes C, Gil J, Tauler A, Ambrosio S: Histone deacetylase inhibition induces apoptosis and autophagy in human neuroblastoma cells. Cancer Lett. 2012, 318 (1): 42-52. 10.1016\/j.canlet.2011.11.036.","journal-title":"Cancer Lett"},{"issue":"4","key":"320_CR27","doi-asserted-by":"publisher","first-page":"e34265","DOI":"10.1371\/journal.pone.0034265","volume":"7","author":"HJ Xie","year":"2012","unstructured":"Xie HJ, Noh JH, Kim JK, Jung KH, Eun JW, Bae HJ, Kim MG, Chang YG, Lee JY, Park H: HDAC1 inactivation induces mitotic defect and caspase-independent autophagic cell death in liver cancer. PLoS One. 2012, 7 (4): e34265-10.1371\/journal.pone.0034265.","journal-title":"PLoS One"},{"issue":"14","key":"320_CR28","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1182\/blood-2009-05-220889","volume":"114","author":"M Gupta","year":"2009","unstructured":"Gupta M, Ansell SM, Novak AJ, Kumar S, Kaufmann SH, Witzig TE: Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood. 2009, 114 (14): 2926-2935. 10.1182\/blood-2009-05-220889.","journal-title":"Blood"},{"issue":"8","key":"320_CR29","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.4161\/auto.6.8.13365","volume":"6","author":"YL Liu","year":"2010","unstructured":"Liu YL, Yang PM, Shun CT, Wu MS, Weng JR, Chen CC: Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma. Autophagy. 2010, 6 (8): 1057-1065. 10.4161\/auto.6.8.13365.","journal-title":"Autophagy"},{"issue":"5","key":"320_CR30","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.cellsig.2009.01.004","volume":"21","author":"RM Memmott","year":"2009","unstructured":"Memmott RM, Dennis PA: Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal. 2009, 21 (5): 656-664. 10.1016\/j.cellsig.2009.01.004.","journal-title":"Cell Signal"},{"issue":"9","key":"320_CR31","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1038\/onc.2009.512","volume":"29","author":"WC Gustafson","year":"2010","unstructured":"Gustafson WC, Weiss WA: Myc proteins as therapeutic targets. Oncogene. 2010, 29 (9): 1249-1259. 10.1038\/onc.2009.512.","journal-title":"Oncogene"},{"issue":"19","key":"320_CR32","doi-asserted-by":"publisher","first-page":"7803","DOI":"10.1158\/0008-5472.CAN-09-0910","volume":"69","author":"BS Balakumaran","year":"2009","unstructured":"Balakumaran BS, Porrello A, Hsu DS, Glover W, Foye A, Leung JY, Sullivan BA, Hahn WC, Loda M, Febbo PG: MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy. Cancer Res. 2009, 69 (19): 7803-7810. 10.1158\/0008-5472.CAN-09-0910.","journal-title":"Cancer Res"},{"issue":"4","key":"320_CR33","doi-asserted-by":"publisher","first-page":"e33813","DOI":"10.1371\/journal.pone.0033813","volume":"7","author":"MJ Kluk","year":"2012","unstructured":"Kluk MJ, Chapuy B, Sinha P, Roy A, Dal Cin P, Neuberg DS, Monti S, Pinkus GS, Shipp MA, Rodig SJ: Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS One. 2012, 7 (4): e33813-10.1371\/journal.pone.0033813.","journal-title":"PLoS One"},{"issue":"8","key":"320_CR34","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1038\/leu.2009.41","volume":"23","author":"QL Zhang","year":"2009","unstructured":"Zhang QL, Wang L, Zhang YW, Jiang XX, Yang F, Wu WL, Janin A, Chen Z, Shen ZX, Chen SJ: The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia\/lymphoma cells apoptosis. Leukemia. 2009, 23 (8): 1507-1514. 10.1038\/leu.2009.41.","journal-title":"Leukemia"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-6-53.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:50:06Z","timestamp":1630543806000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/1756-8722-6-53"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,18]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["320"],"URL":"https:\/\/doi.org\/10.1186\/1756-8722-6-53","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,18]]},"assertion":[{"value":"13 May 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"53"}}